Why the study?
Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and begins with the first dose.
Does dexrazoxane initiated on day 1 prevent doxorubicin cardiac toxicity in patients with soft-tissue sarcomas?
Does dexrazoxane initiated on day 1 prevent doxorubicin cardiac toxicity in patients with soft-tissue sarcomas?
Dexrazoxane can be safely initiated on day 1 of doxorubicin therapy to prevent cardiotoxicity without compromising antitumor efficacy.
Supports day-1 dexrazoxane with doxorubicin; leaves open randomized confirmation of cardiac benefit in sarcomas.
Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity, allowing doxorubicin administration beyond the reported maximum lifetime dose. See related articles by Van Tine et al., p. 3854 and Jones et al., p. 3861
No takes yet. Share an insight, caveat, or question.
Benjamin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: